Adrenal Insufficiency in Septic Shock
Phase 4
Terminated
- Conditions
- Septic ShockAcute Adrenal Insufficiency
- Interventions
- Drug: Corticosteroid
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00842933
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Phase 2
Withdrawn
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Registration Number
- NCT00837174
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Phase 1
Terminated
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00522249
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00521781
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00521274
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00450008
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 55
- Registration Number
- NCT00448149
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00448409
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00448097
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00447473
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States